Trial Profile
A 3-Part, Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64140284 in Healthy Subjects
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs JNJ-64140284 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Research & Development
- 23 Oct 2017 Status changed from suspended to discontinued as SAE has occured. As a measure of precaution, the trial has been stopped.
- 22 Sep 2017 Status changed from recruiting to suspended as SAE has occured. As a measure of precaution, the dosing of JNJ-64140284 has been suspended for all subjects participating in the trial
- 16 Jun 2017 New trial record